biotin endogen blockers (Roche)
Roche manufactures this product 
86
Structured Review
Roche
biotin endogen blockers
Biotin Endogen Blockers, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotin+endogen+blockers/10__1158_slash_1535___7163__mct___06___0104-69-21-24
Average 86 stars, based on 1 article reviews
Biotin Endogen Blockers, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/biotin+endogen+blockers/10__1158_slash_1535___7163__mct___06___0104-69-21-24
Average 86 stars, based on 1 article reviews
biotin endogen blockers - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Incubation:Article Title: Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner Article Snippet: Background: Preclinical and clinical studies have shown that the proteasome inhibitor bortezomib (PS341, Velcade) is highly effective when combined with chemotherapeutic agents.. The value of trastuzumab (Herceptin) in HER-2–positive (3+ score by immunohistochemistry or fluorescence in situ hybridization positive) breast cancer is also known; however, the response rate is <40% for metastatic breast cancer.. These two pharmacologic agents prevent nuclear factor-KB (NF-KB) activation and induce nuclear accumulation of the cyclin-dependent kinase inhibitor p27, suggesting that combining bortezomib with trastuzumab could increase trastuzumab efficacy. Staining:Article Title: Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner Article Snippet: Background: Preclinical and clinical studies have shown that the proteasome inhibitor bortezomib (PS341, Velcade) is highly effective when combined with chemotherapeutic agents.. The value of trastuzumab (Herceptin) in HER-2–positive (3+ score by immunohistochemistry or fluorescence in situ hybridization positive) breast cancer is also known; however, the response rate is <40% for metastatic breast cancer.. These two pharmacologic agents prevent nuclear factor-KB (NF-KB) activation and induce nuclear accumulation of the cyclin-dependent kinase inhibitor p27, suggesting that combining bortezomib with trastuzumab could increase trastuzumab efficacy. |